Serum 14-3-3η A Predictor Of Secondary Sjögren’s Syndrome In SLE
Do you have a patient with Systemic Lupus Erythematosus (SLE) that you suspect may also have Sjögren’s Syndrome (SS)?
With shared clinical and serological features, overlapping SS with SLE is a comorbidity that is often challenging to identify to promptly assist clinical management. This may also lead to misdiagnoses of other connective tissue disorders.
New data on 14-3-3η (eta) enhances the detection rates of patients with secondary SS
- Serum 14-3-3η levels were found to be elevated in SLE patients with secondary SS compared to those with SLE without SS
- ROC analysis showed serum 14-3-3η levels as a predictor of SLE with secondary SS
- Levels of 14-3-3η significantly correlate with clinical and serological parameters (occular siccia, anti-LA and anti-Ro) in patients with secondary SS among SLE patients
Whether serum 14-3-3η levels are used alone in management of disease or in combination with other serological measurements, 14-3-3η clearly improves the diagnostic utility of patients with autoimmune conditions.
Hammam, N., Gamal, N.M., Elzohri, M.H. et al. Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren’s syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis. Clin Rheumatol (2020). https://doi.org/10.1007/s10067-020-05033-3